Cell Bio Human Tech Q1 2026 Consolidated Revenue 12.7B KRW… Up 54% YoY

Consolidated Q1 2026 revenue 12.75B KRW (up 54% YoY from 8.29B), operating profit 1.46B, net income 1.82B.
Separate Q1 2026 revenue 10.49B, operating profit 0.76B, net income 1.25B.
Issued two zero-coupon private exchangeable bonds in Sep & Dec 2025 (3.5B and 6.0B KRW; conversion prices 10,236/9,680 KRW).
On Apr 14, 2026, entered trust agreement for 0.5B KRW share buyback (shareholder return).
On Apr 9, 2026, decided to acquire land and buildings for 5.4B KRW (production expansion).
On May 4, 2026, completed capital reduction of 3,688 fractional shares.
Credit rating upgraded to BBB+ (NICE Information Service, from BBB0).
Consolidated debt-to-equity ratio 47.7%, net debt ratio 2.5% (sound financial structure).
Inventory 15.1B KRW, allowance for doubtful accounts 0.92B (full provision for long-term receivables).

ADVERTISEMENT (250px+)